British American Tobacco (BTI) and ADOCIA (ADOCY) Head-To-Head Comparison

British American Tobacco (NYSE: BTI) and ADOCIA (OTCMKTS:ADOCY) are both consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Earnings & Valuation

This table compares British American Tobacco and ADOCIA’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
British American Tobacco $26.15 billion 4.29 $48.37 billion $3.68 14.32
ADOCIA $24.89 million 5.25 -$8.73 million N/A N/A

British American Tobacco has higher revenue and earnings than ADOCIA.

Profitability

This table compares British American Tobacco and ADOCIA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
British American Tobacco N/A N/A N/A
ADOCIA N/A N/A N/A

Dividends

British American Tobacco pays an annual dividend of $2.02 per share and has a dividend yield of 3.8%. ADOCIA does not pay a dividend. British American Tobacco pays out 54.9% of its earnings in the form of a dividend.

Insider & Institutional Ownership

8.9% of British American Tobacco shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for British American Tobacco and ADOCIA, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
British American Tobacco 0 2 8 0 2.80
ADOCIA 0 0 0 0 N/A

British American Tobacco presently has a consensus target price of $78.50, suggesting a potential upside of 49.01%. Given British American Tobacco’s higher probable upside, equities research analysts clearly believe British American Tobacco is more favorable than ADOCIA.

Volatility & Risk

British American Tobacco has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, ADOCIA has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.

Summary

British American Tobacco beats ADOCIA on 7 of the 9 factors compared between the two stocks.

About British American Tobacco

British American Tobacco p.l.c. provides cigarettes and other tobacco products worldwide. It manufactures vapour and tobacco heating products; oral tobacco and nicotine products, such as snus and moist snuff; cigars; and e-cigarettes. The company offers its products under the Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Vogue, Viceroy, Kool, Peter Stuyvesant, Craven A, Benson & Hedges, John Player Gold Leaf, State Express 555, and Shuang Xi brands. The company sells its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is headquartered in London, the United Kingdom.

About ADOCIA

Adocia Société Anonyme, a clinical-stage biotechnology company, develops medicines for the treatment of diabetes from already-approved therapeutic molecules. Its proprietary BioChaperone technological platform is designed and developed from polymers, oligomers, and small organic compounds to enhance the effectiveness and/or safety of therapeutic proteins. The company’s clinical product pipeline includes four insulin formulations, including BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analogs; HinsBet U100, rapid-acting formulation of human insulin; and BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro. It is also developing six preclinical products, such as BioChaperone Human Glucagon, an aqueous formulation of human glucagon; BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide that are combinations of insulin glargine with GLP-1s; BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide, which are combinations of insulin lispro with synergistic prandial hormones; and HinsBet U500, a concentrated, rapid-acting formulation of human insulin. The company was founded in 2005 and is headquartered in Lyon, France.

Receive News & Ratings for British American Tobacco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for British American Tobacco and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply